Trinity Biotech plc (NASDAQ:TRIB)’s share price was up 2.4% during trading on Thursday . The stock traded as high as $11.18 and last traded at $10.85, with a volume of 161,589 shares traded. The stock had previously closed at $10.60.

Several equities analysts recently commented on TRIB shares. Zacks Investment Research upgraded Trinity Biotech plc from a “sell” rating to a “hold” rating in a research report on Wednesday, June 22nd. Roth Capital restated a “buy” rating on shares of Trinity Biotech plc in a research report on Thursday, April 21st. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Trinity Biotech plc presently has an average rating of “Buy” and a consensus price target of $18.00.

The stock’s 50-day moving average is $11.11 and its 200 day moving average is $10.98. The firm has a market capitalization of $250.80 million and a PE ratio of 40.34.

Trinity Biotech plc (NASDAQ:TRIB) last announced its quarterly earnings results on Tuesday, April 19th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.08 by $0.02. Analysts expect that Trinity Biotech plc will post $0.21 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of TRIB. Stephens Inc. AR increased its position in Trinity Biotech plc by 4.3% in the fourth quarter. Stephens Inc. AR now owns 123,171 shares of the company’s stock valued at $1,448,000 after buying an additional 5,045 shares during the last quarter. US Bancorp DE increased its position in Trinity Biotech plc by 103.1% in the fourth quarter. US Bancorp DE now owns 238,825 shares of the company’s stock valued at $2,808,000 after buying an additional 121,214 shares during the last quarter. Lapides Asset Management LLC increased its position in Trinity Biotech plc by 50.0% in the fourth quarter. Lapides Asset Management LLC now owns 554,300 shares of the company’s stock valued at $6,519,000 after buying an additional 184,800 shares during the last quarter. Royce & Associates LLC increased its position in Trinity Biotech plc by 17.9% in the fourth quarter. Royce & Associates LLC now owns 702,598 shares of the company’s stock valued at $8,263,000 after buying an additional 106,500 shares during the last quarter. Finally, Bank of Montreal Can purchased a new position in Trinity Biotech plc during the fourth quarter valued at approximately $13,045,000.

Trinity Biotech plc (Trinity Biotech) develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. These products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.